Malcolm Lloyd-Smith Sells 9,000 Shares of Neurocrine Biosciences, Inc. (NBIX) Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Malcolm Lloyd-Smith sold 9,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 7th. The stock was sold at an average price of $110.01, for a total transaction of $990,090.00. Following the transaction, the insider now owns 21,018 shares in the company, valued at $2,312,190.18. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Shares of NASDAQ:NBIX traded up $1.75 during mid-day trading on Monday, hitting $90.02. The company had a trading volume of 813,400 shares, compared to its average volume of 794,759. The firm has a market capitalization of $8.00 billion, a P/E ratio of -55.57, a P/E/G ratio of 22.58 and a beta of 0.91. Neurocrine Biosciences, Inc. has a one year low of $68.22 and a one year high of $126.98.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Monday, November 5th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.04. Neurocrine Biosciences had a net margin of 2.40% and a return on equity of 2.54%. The company had revenue of $151.80 million during the quarter, compared to analyst estimates of $151.51 million. During the same quarter in the previous year, the business posted ($0.13) EPS. Neurocrine Biosciences’s revenue for the quarter was up 149.7% compared to the same quarter last year. Equities research analysts anticipate that Neurocrine Biosciences, Inc. will post 0.19 EPS for the current fiscal year.

Several large investors have recently modified their holdings of NBIX. Capital International Investors purchased a new stake in Neurocrine Biosciences during the third quarter valued at about $31,721,000. Victory Capital Management Inc. lifted its holdings in Neurocrine Biosciences by 60.5% during the third quarter. Victory Capital Management Inc. now owns 605,135 shares of the company’s stock valued at $74,402,000 after purchasing an additional 228,163 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Neurocrine Biosciences by 2.7% during the third quarter. Vanguard Group Inc. now owns 7,772,236 shares of the company’s stock valued at $955,597,000 after purchasing an additional 204,065 shares during the last quarter. NorthCoast Asset Management LLC purchased a new stake in Neurocrine Biosciences during the third quarter valued at about $22,180,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in Neurocrine Biosciences by 192.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 249,900 shares of the company’s stock valued at $30,725,000 after purchasing an additional 164,306 shares during the last quarter. 96.88% of the stock is currently owned by institutional investors.

A number of equities research analysts recently weighed in on the stock. Stifel Nicolaus boosted their price target on shares of Neurocrine Biosciences from $137.00 to $142.00 and gave the stock a “buy” rating in a research note on Thursday, September 20th. Oppenheimer set a $140.00 target price on shares of Neurocrine Biosciences and gave the company a “buy” rating in a research note on Tuesday, September 4th. Leerink Swann began coverage on shares of Neurocrine Biosciences in a research note on Monday, November 12th. They issued a “market perform” rating and a $110.00 target price for the company. Piper Jaffray Companies set a $111.00 target price on shares of Neurocrine Biosciences and gave the company a “buy” rating in a research note on Tuesday, November 6th. Finally, Cantor Fitzgerald set a $150.00 price target on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a research report on Thursday, September 20th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seventeen have given a buy rating to the company. Neurocrine Biosciences has an average rating of “Buy” and a consensus target price of $124.88.

WARNING: “Malcolm Lloyd-Smith Sells 9,000 Shares of Neurocrine Biosciences, Inc. (NBIX) Stock” was originally published by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this report on another website, it was stolen and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be accessed at https://www.baseballdailydigest.com/news/2018/12/03/neurocrine-biosciences-inc-nbix-insider-sells-990090-00-in-stock.html.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease.

Featured Story: Why Dividend Stocks May Be Right for You

Insider Buying and Selling by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply